SANDU PHARMACEUTICALS LIMITED
CIN:L24233GA1985PLC001587
Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2026-27/BSE/510

Dated:14.11.2026

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 14th November 2026 with Scrip Code 524703.

Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015

A Meeting of the Board of Directors of the Company duly convened on Saturday, 14th November 2026 at 04:00 p.m. and concluded at 6.40p.m. discussed the following business:

Approval of Unaudited Financial Results for the quarter and half year ended 30h September. 2026. The Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 prepared in compliance with Ind-AS and the Limited Review Report issued by M/s Dave & Dave Chartered Accountants, Mumbai, [Firm Registration. No. 102163W], Statutory Auditors of the Company pursuant to Regulation 33 of Chapter IV of SEBI (Listing Obligations & Disclosure Requirements) Regulations ,2015 have been reviewed by the Audit Committee and placed before the Board of Directors of the Company in their meeting held today ON 14TH November 2026. The same are approved and taken on record by the Board.

The Unaudited Financial Results for the quarter and half year ended 30th September 2026 and the Limited Review Report are also available in the website of the company at www.sandu.in and are enclosed herewith for your kind perusal.

For Sandu Pharmaceuticals Limited

PRATIKA MHAMBRAY

Digitally signed by PRATIKA MHAMBRAY
Date: 2026.11.14 18:47:22 +05'30'

Pratika Mhambray
Company Secretary & Compliance Officer
ACS :36512

SANDU PHARMACEUTICALS LTD

SANDU TRUSTED IN AYURVEDA

Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 6920 4400, E-mail: info@sandu.in, Web: www.sandu.in

SANDU PHARMACEUTICALS LIMITED

Standalone Statement of Profit and Loss for the Period ended 30th Sept, 2026

(Rs in lakhs)

Particulars	Note No.	3 Months ended			Half Yearly		Year ended
		30th Sept 2026	30th June 2026	30th Sept 2025	30th Sept 2026	30th Sept 2025	31st March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
INCOME							
Revenue From Operations	18	1942.88	1638.88	1762.11	3581.76	3432.01	6993.45
Other Income	19	8.71	1.74	4.79	10.44	6.56	44.44
Total Income		**1951.59**	**1640.62**	**1766.91**	**3592.20**	**3438.58**	**7037.89**
EXPENSES							
Cost of materials consumed	20	159.08	234.10	244.85	393.18	435.94	1101.18
Purchases of Stock-in-Trade	21	542.23	443.24	587.84	985.47	946.59	1648.07
Changes in inventories of finished goods,Stock-in - Trade and work-in-progress	22	225.98	-23.36	.02	202.62	333.49	407.95
Employee benefits expense	23	240.12	279.45	263.79	519.57	530.15	1069.08
Finance costs	24	2.60	2.99	2.66	5.59	5.29	11.21
Depreciation and amortization expense	3	16.55	16.37	16.87	32.92	34.63	67.70
Other expenses	25	679.11	651.78	579.42	1330.89	1047.15	2467.16
Total expenses		**1865.67**	**1604.57**	**1695.46**	**3470.24**	**3333.25**	**6772.35**
Profit/(loss) before exceptional items and tax		85.91	36.05	71.45	121.97	105.32	265.54
Exceptional Items / Prior Period Adjustment							.00
PROFIT/(LOSS) BEFORE TAX		**85.91**	**36.05**	**71.45**	**121.97**	**105.32**	**265.54**
Tax expense:	26						
Current tax		-20.40	-9.37	-19.71	-29.77	-29.39	-66.64
Deferred tax		13.01	-3.86	-.54	9.15	-1.17	-10.41
Short / (Excess) Tax Provision		.00	.00	1.22	.00	.00	-11.89
PROFIT (LOSS) FOR THE PERIOD		**78.52**	**22.82**	**52.43**	**101.35**	**74.76**	**176.61**
OTHER COMPREHENSIVE INCOME							
Items that will not be reclassified to profit or loss in Subsequent Periods :							
Remeasurement gains/(losses) on post employment defined benefit plans		.00	.00	.00	.00	.00	8.11
Fair value changes of investments		15.74	17.84	16.13	33.58	35.76	74.61
Income tax relating to items that will not be reclassified to profit or loss		-2.03	-2.32	-2.24	-4.35	-11.55	-16.38
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)		**13.70**	**15.52**	**13.88**	**29.23**	**24.21**	**66.35**
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)		**92.23**	**38.35**	**66.31**	**130.57**	**98.97**	**242.95**
Paid Up Equity Capital (Face Value of Rs 10/- Per share)		966.10	966.10	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE	27						
Basic		0.81	0.37	0.54	1.05	0.77	1.83
Diluted		0.81	0.37	0.54	1.05	0.77	1.83

Balram Viswanathan

Digitally signed by Balram Viswanathan
Date: 2026.11.14 18:48:27 +05'30'

SANDU PHARMACEUTICALS LTD MUMBAI

For Sandu Pharmaceuticals Ltd

Balram Viswanathan
Managing Director
DIN :- 10245195

Place :- Mumbai
Dated : 14th Nov 2026

SANDU
TRUSTED IN AYURVEDA

SANDU PHARMACEUTICALS LTD

Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 6920 4400. E-mail: info@sandu.in. Web: www.sandu.in

SANDU PHARAMACEUTICALS LIMITED

Standalone Balance Sheet as at 30th Sept, 2026

(Rs in lakhs)

PARTICULARS	As at 30th Sept 2026	As at 31st March, 2026
	Amount (`)	Amount (`)
ASSETS		
Non-current assets		
Property, Plant and Equipment	848.22	868.47
Right of use assets	930.35	942.13
Capital Work in Progress	10.91	6.41
Other Intangible Assets	1.85	1.86
Financial Assets		
Investments	1242.31	1229.80
Other Financial Asset	.00	3.08
Other Non-Current Assets	12.44	3.24
	3046.09	**3054.99**
Current assets		
Inventories	1133.48	1047.13
Financial Assets		
Trade receivables	783.04	541.09
Cash and cash equivalents	314.27	590.77
Bank balances other than 9 (a) above	83.72	94.82
Other current assets	357.08	258.11
	2671.59	**2531.94**
	5717.67	**5586.93**
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	966.10	966.10
Other Equity	3435.20	3401.23
	4401.30	**4367.33**
Non-current liabilities		
Financial Liabilities		
Finance Lease obligations	30.86	30.95
Deferred tax liabilities (Net)	141.63	146.44
	172.49	**177.39**
Current liabilities		
Financial Liabilities		
Finance Lease obligations	6.43	10.98
Trade payables Due to :		
Micro and Small Enterprises	60.26	61.72
Other than Micro and Small Enterprises	478.27	385.03
Other Financial Liabilities	39.75	31.27
Other current liabilities	132.07	206.59
Provisions	427.11	346.63
	1143.88	**1042.21**
	5717.67	**5586.93**

Balram Viswanathan

Digitally signed by Balram Viswanathan
Date: 2026.11.14 18:48:54 +05'30'

SANDU PHARMACEUTICALS LTD MUMBAI

For Sandu Pharmaceuticals Ltd

Balram Viswanathan
Managing Director
DIN :- 10245195

Place :- Mumbai
Dated : 14th Nov 2026

SANDU
TRUSTED IN AYURVEDA

SANDU PHARMACEUTICALS LTD

Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 6920 4400, E-mail: info@sandu.in, Web: www.sandu.in

SANDU PHARMACEUTICALS LIMITED

Standalone Statement of Cash Flow for the period ended 30th Sept, 2026

(Rs in lakhs)

Particulars	As at 30th Sept 2026		As at 31st March, 2026	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		121.97		265.54
Adjustments for:				
Depreciation and amortisation expenses	32.92		67.70	
Finance costs	5.59		11.21	
Interest income	-10.44		-5.89	
Other Income	.00		.00	
Loss on Sale of Investment in Subsidary Sandu Phytoceuticals P Ltd	.00		.00	
Allowance for doubtful debts / expected credit losses - trade receivable	4.04		48.60	
Equity Instruments through Other Comprehensive Income	.00		.00	
Re-measurement gains/losses on employee defined benefit plans	.00		8.11	
		32.10		129.72
Operating profit / (loss) before changes in operating assets & liabilities		154.06		395.26
Changes in operating assets				
(increase) / decrease in inventories	-86.34		367.73	
(increase) / decrease in Trade receivables	-245.98		-113.96	
(increase) / decrease in other operating assets	-108.17		25.71	
Changes in operating liabilities				
(increase) / decrease in trade payables	91.77		-2.03	
(increase) / decrease in other operating liabilities	15.99	-332.74	13.84	291.30
Cash Generated from operation		-178.67		686.56
Income Tax Paid		-31.31		-74.98
Net Cash flow from Operating activites		-209.98		611.58
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	-5.39		-72.00	
Proceeds from Maturity of Fixed Deposits placed with Banks	14.19		70.00	
Fixed deposits placed with banks	.00		-28.00	
Interest received	10.44		5.89	
Other Income	.00		.00	
Proceed from Sale of Invesetment in Subsidary Sandu Phytoceuticals P Ltd	.00		.00	
Proceeds from Sales of Mutual Funds /Shares	33.58		74.61	
Purchases of Mutual fund / Shares designated at FVTOCI	-12.51		-107.38	
Net cash flow from / (used in) investing activities (B)		40.32		-56.88
C. Cash flow from financing activities				
Finance lease obligations	-4.64		-5.82	
Finance cost	-5.59		-11.21	
Dividend Paid	-96.61		-77.29	
Net cash flow from / (used in) financing activities (C)		-106.84		-94.32
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		-276.50		460.38
Cash and cash equivalents at the beginning of the year		590.77		130.39
Cash and cash equivalents at the end of the year		314.27		590.77

Notes:

1. The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
2. For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Reconciliation of cash and cash equivalents with the balance sheet :

(Rs in lakhs)

Particulars	As at 30th Sept 2026	As at 31st March, 2026
As per Balance Sheet -note 11(a)	314.27	590.77
Balance as per statement of cash flows	**314.27**	**590.77**

Balram Viswanathan

Digitally signed by Balram Viswanathan
Date: 2026.11.14 18:49:13 +05'30'

For Sandu Pharmaceuticals Ltd

Balram Viswanathan
Managing Director
DIN :- 10245195

Place :- Mumbai
Dated : 14th Nov 2026

SANDU
TRUSTED IN AYURVEDA

SANDU PHARMACEUTICALS LTD

Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 6920 4400, E-mail: info@sandu.in, Web: www.sandu.in

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.

2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.

3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 14/11/2026.

4. The Figures for the quarter ended 30th Sept, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to Six months ended of the respective financial year..

5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

Balram Viswanathan

Digitally signed by Balram Viswanathan
Date: 2026.11.14 18:49:35 +05'30'

SANDU PHARMACEUTICALS LTD MUMBAI

For Sandu Pharmaceuticals Ltd

Date: - 14/11/2026

Balram Viswanathan
Managing Director
DIN no: - 10245195

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30th SEPTEMBER, 2026

To,
The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and half year ended on 30th September, 2026, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement *(SRE) 2410,* "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

316 Gold Mohur Building, 174 P[illegible]et, Marine Lines Mumbai– 400002.
Ph: 4978 6557 E-mail : cadaveanddave@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s. DAVE & DAVE
Chartered Accountants
Firm Registration Number: 102163W

Lilashankar Dave
(Partner)
Membership Number: 042889
Place: Mumbai
Date :14th November, 2026
UDIN- 26042889GOLXBC9348

316 Gold Mohur Building, 174 Princess Street, Marine Lines Mumbai– 400002.
Ph: 4978 6557 E-mail : cadaveanddave@gmail.com